Life Science Focus https://www.lifesciencefocus.com The latest articles with business news. en Denmark compensates patients after vision loss linked to Novo drugs https://www.lifesciencefocus.com/article/view/1257848/denmark_compensates_patients_after_vision_loss_linked_to_novo_drugs?ref=rss An increasing number of patients in Denmark are being granted compensation after developing the serious eye condition NAION following treatment with Novo Nordisk’s drugs Wegovy and Ozempic. Fri, 20 Nov 2026 10:22:17 +0100 https://www.lifesciencefocus.com/article/view/1257848 Norway and Finland: The life science researchers among the world’s most cited https://www.lifesciencefocus.com/article/view/1257711/norway_and_finland_the_life_science_researchers_among_the_worlds_most_cited?ref=rss From cardiovascular medicine to diabetes and physical activity, researchers affiliated with Norwegian and Finnish institutions feature on Clarivate’s 2026 list of the world’s most highly cited scientists. Life Science Focus has compiled a selection of 17 researchers working in life science and related fields across the two countries. Fri, 20 Nov 2026 08:32:46 +0100 https://www.lifesciencefocus.com/article/view/1257711 Medivir scores US regulatory breakthrough for bone disease drug https://www.lifesciencefocus.com/article/view/1257751/medivir_scores_us_regulatory_breakthrough_for_bone_disease_drug?ref=rss Medivir has achieved an important regulatory milestone in the US for its drug candidate MIV-711, which is being developed to treat the rare bone disorder osteogenesis imperfecta. Thu, 19 Nov 2026 16:01:16 +0100 https://www.lifesciencefocus.com/article/view/1257751 Pfizer bets big on next-generation CAR-T https://www.lifesciencefocus.com/article/view/1257721/pfizer_bets_big_on_nextgeneration_cart?ref=rss Pfizer is entering the in vivo CAR-T race by licensing three preclinical candidates from Chinese biotech company Starna Therapeutics. Thu, 19 Nov 2026 14:30:55 +0100 https://www.lifesciencefocus.com/article/view/1257721 Sanofi’s new rabies vaccine wins EU approval https://www.lifesciencefocus.com/article/view/1257637/sanofis_new_rabies_vaccine_wins_eu_approval?ref=rss Rabies attacks the central nervous system and is incurable once symptoms appear. Sanofi’s new rabies vaccine has now received EU approval, offering a longer shelf life and improved temperature stability compared with the company’s previous vaccines. Thu, 19 Nov 2026 11:07:05 +0100 https://www.lifesciencefocus.com/article/view/1257637 Schizophrenia drug shows promise in Alzheimer’s psychosis https://www.lifesciencefocus.com/article/view/1257612/schizophrenia_drug_shows_promise_in_alzheimers_psychosis?ref=rss A schizophrenia drug from Bristol Myers Squibb has shown promising results against psychotic symptoms in patients with Alzheimer's disease in two Phase 3 trials. Thu, 19 Nov 2026 10:39:04 +0100 https://www.lifesciencefocus.com/article/view/1257612 Here are the Danish researchers on the global most-cited list https://www.lifesciencefocus.com/article/view/1257608/here_are_the_danish_researchers_on_the_global_mostcited_list?ref=rss Thirty-seven researchers affiliated with Danish institutions feature in this year’s selection of the world’s most highly cited scientists in medicine and related fields. Among them are internationally recognised names in neuroscience, migraine and diabetes research. Thu, 19 Nov 2026 10:33:18 +0100 https://www.lifesciencefocus.com/article/view/1257608 LEO Pharma puts IPO plans on hold – for now: “There will be no IPO in 2026” https://www.lifesciencefocus.com/article/view/1257536/leo_pharma_puts_ipo_plans_on_hold_for_now_there_will_be_no_ipo_in_2026?ref=rss Danish pharmaceutical company LEO Pharma will not go public this year. Thu, 19 Nov 2026 08:23:16 +0100 https://www.lifesciencefocus.com/article/view/1257536 Stratipath disputes Swedish council’s assessment: “Not accurate at all” https://www.lifesciencefocus.com/article/view/1257494/stratipath_disputes_swedish_councils_assessmentnot_accurate_at_all?ref=rss Sweden’s Medical Technology Product Council has advised regions against using Stratipath’s AI tool to inform treatment decisions for a group of breast cancer patients. The company is contesting the assessment, arguing that the council has not considered all the available evidence. Wed, 18 Nov 2026 15:59:41 +0100 https://www.lifesciencefocus.com/article/view/1257494 46 Sweden-based medical researchers named among world’s most cited https://www.lifesciencefocus.com/article/view/1257386/46_swedenbased_medical_researchers_named_among_worlds_most_cited?ref=rss Forty-six researchers affiliated with Swedish institutions have been named on Clarivate’s annual list of the world’s most highly cited scientists in medicine and related fields. Eleven did not appear in last year’s selection, while seven have dropped off. See Life Science Focus’s full compilation below. Wed, 18 Nov 2026 12:17:49 +0100 https://www.lifesciencefocus.com/article/view/1257386 Eli Lilly strikes cancer research deal with Stipple Bio worth up to USD 5.9 billion https://www.lifesciencefocus.com/article/view/1257367/eli_lilly_strikes_cancer_research_deal_with_stipple_bio_worth_up_to_usd_59_billion?ref=rss US pharma company Eli Lilly has entered into a strategic research and licensing agreement with privately held biotech company Stipple Bio to develop novel targeted cancer treatments. Wed, 18 Nov 2026 11:37:12 +0100 https://www.lifesciencefocus.com/article/view/1257367 Biogen reports progress with tau-targeting Alzheimer's drug https://www.lifesciencefocus.com/article/view/1257354/biogen_reports_progress_with_tautargeting_alzheimers_drug?ref=rss In a Phase 2 trial, Biogen has reported what it desribes to be the first evidence that a tau-targeting treatment may slow cognitive decline in Alzheimer's disease. Wed, 18 Nov 2026 11:10:56 +0100 https://www.lifesciencefocus.com/article/view/1257354 White House withdraws nomination of new FDA chief https://www.lifesciencefocus.com/article/view/1257347/white_house_withdraws_nomination_of_new_fda_chief?ref=rss Just hours before a crucial vote, the White House has withdrawn the nomination of Heidi Overton to lead the US Food and Drug Administration (FDA), according to media reports. The decision follows weeks of growing opposition in the Senate. Wed, 18 Nov 2026 10:58:28 +0100 https://www.lifesciencefocus.com/article/view/1257347 AI drug developer raises $5 billion in new round https://www.lifesciencefocus.com/article/view/1257334/ai_drug_developer_raises_5_billion_in_new_round?ref=rss The British AI drug developer Isomorphic Labs has raised $5 billion in an oversubscribed Series C funding round. Wed, 18 Nov 2026 10:33:17 +0100 https://www.lifesciencefocus.com/article/view/1257334 EU approval brings new hope for pancreatic cancer patients: “You can certainly call it a breakthrough” https://www.lifesciencefocus.com/article/view/1257051/eu_approval_brings_new_hope_for_pancreatic_cancer_patients_you_can_certainly_call_it_a_breakthrough?ref=rss Pancreatic cancer is notoriously difficult to treat and carries a poor prognosis. Despite the significant unmet medical need, there have been few advances in the field in recent years – until now. A new drug, approved in the EU on Monday, is raising hopes, while several other promising treatments are also in development. Tue, 17 Nov 2026 09:43:06 +0100 https://www.lifesciencefocus.com/article/view/1257051 KD Ventures appoints Johan Dighed as new CEO https://www.lifesciencefocus.com/article/view/1257046/kd_ventures_appoints_johan_dighed_as_new_ceo?ref=rss The life science investment company KD Ventures has appointed Johan Dighed as its new CEO, taking office on 16 November. He succeeds Viktor Drvota, who is leaving the position after more than nine years. Tue, 17 Nov 2026 09:33:31 +0100 https://www.lifesciencefocus.com/article/view/1257046 Shingles vaccine tops suspected side effect reports among over-65s https://www.lifesciencefocus.com/article/view/1256973/shingles_vaccine_tops_suspected_side_effect_reports_among_over65s?ref=rss The shingles vaccine tops the list of suspected adverse drug reactions reported among older people in Sweden. Nearly 4,000 members of the public have reported suspected side effects from medicines to the Swedish Medical Products Agency so far this year. Tue, 17 Nov 2026 07:27:43 +0100 https://www.lifesciencefocus.com/article/view/1256973 Lilly strikes another billion-dollar deal – 15 acquisitions this year alone https://www.lifesciencefocus.com/article/view/1256985/lilly_strikes_another_billiondollar_deal_15_acquisitions_this_year_alone?ref=rss Eli Lilly is continuing its expansion strategy with the acquisition of blood cancer biotech Calytrix Bio in a deal worth up to USD 1.5 billion. Mon, 16 Nov 2026 16:47:30 +0100 https://www.lifesciencefocus.com/article/view/1256985 <![CDATA[J&J bets USD 3.3 billion on phase 3 eye drug]]> https://www.lifesciencefocus.com/article/view/1256965/jj_bets_usd_33_billion_on_phase_3_eye_drug?ref=rss Mon, 16 Nov 2026 15:36:45 +0100 https://www.lifesciencefocus.com/article/view/1256965 AstraZeneca expands Karolinska partnership – adds obesity research https://www.lifesciencefocus.com/article/view/1256869/astrazeneca_expands_karolinska_partnership_adds_obesity_research?ref=rss AstraZeneca is expanding its research collaboration with Karolinska Institutet and Karolinska University Hospital. The pharmaceutical company is now investing just over SEK 30 million in four projects, with obesity added as a new research area. Mon, 16 Nov 2026 13:27:45 +0100 https://www.lifesciencefocus.com/article/view/1256869 Saniona takes fast-acting depression drug into clinical trials https://www.lifesciencefocus.com/article/view/1256872/saniona_takes_fastacting_depression_drug_into_clinical_trials?ref=rss The Danish-Swedish research company Saniona has received clearance to initiate clinical trials in the US with its drug candidate SAN2465 for major depressive disorder (MDD). Mon, 16 Nov 2026 11:07:04 +0100 https://www.lifesciencefocus.com/article/view/1256872 AstraZeneca's new blood pressure drug recommended for EU approval https://www.lifesciencefocus.com/article/view/1256842/astrazenecas_new_blood_pressure_drug_recommended_for_eu_approval?ref=rss AstraZeneca's blood pressure drug Baxfendy (baxdrostat) has received a positive recommendation from the European Medicines Agency's CHMP, paving the way for EU approval. Mon, 16 Nov 2026 10:30:11 +0100 https://www.lifesciencefocus.com/article/view/1256842 Frost Pharma recruits new CEO from SciBase https://www.lifesciencefocus.com/article/view/1256841/frost_pharma_recruits_new_ceo_from_scibase?ref=rss FrostPharma has appointed Pia Renaudin as its new CEO. She will take up the position at the beginning of the year. Mon, 16 Nov 2026 10:27:57 +0100 https://www.lifesciencefocus.com/article/view/1256841 Reports: AstraZeneca cuts 600 jobs in US https://www.lifesciencefocus.com/article/view/1256839/reports_astrazeneca_cuts_600_jobs_in_us?ref=rss While AstraZeneca is planning to invest $50 billion in the US, the company is cutting jobs in its American sales organisation. Around 600 positions are affected, according to Bloomberg. Mon, 16 Nov 2026 10:26:01 +0100 https://www.lifesciencefocus.com/article/view/1256839 Virtuoso wins FDA clearance for bladder surgery robot https://www.lifesciencefocus.com/article/view/1256389/virtuoso_wins_fda_clearance_for_bladder_surgery_robot?ref=rss Two miniature robotic arms inserted through the urethra are designed to make it possible to remove bladder tumours in a single piece. Virtuoso Surgical’s robotic system has now received FDA clearance. Mon, 16 Nov 2026 09:08:42 +0100 https://www.lifesciencefocus.com/article/view/1256389